Developer docs
API playgroundTry for free, no card

Search company profiles

Krouzon Pharmaceuticals

Full company profile

uuid000tpo6

Namestring
Krouzon Pharmaceuticals
Legal namestring
Krouzon Pharmaceuticals, Inc.
Websiteurl
krouzon.com
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, craniosynostosis treatment, FGFR2 inhibitors, pediatric genetic diseases, pharmaceutical drug development
Industry2 codes
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Pediatric Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing pharmacological treatments for rare pediatric diseases. Revenue will be generated through drug commercialization upon regulatory approval, likely via prescription model for orphan/rare disease therapeutics.

krouzon.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Krouzon Pharmaceuticals is developing pharmacological therapeutics for children born with FGFR2-related Syndromic Craniosynostosis syndromes — Pfeiffer, Apert, and Crouzon syndromes. The drug development program focuses on creating disease-modifying treatments that target the root cause of FGFR2 mutations, aiming to restore normal child development and eliminate the need for lifelong invasive surgeries that constitute current standard of care.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Krouzon Pharmaceuticals is developing a pipeline of pharmacological therapeutics for pediatric rare diseases, specifically targeting FGFR2-related Syndromic Craniosynostosis conditions including Pfeiffer syndrome, Apert syndrome, and Crouzon syndrome. The company's drug development program focuses on creating disease-modifying treatments to restore normal child development without the need for lifelong surgeries. These three therapeutic candidates represent Krouzon's core product portfolio in pediatric rare disease therapeutics.

Product and service3 records
1Pfeiffer Syndrome Therapeutic
CategoryTherapeutic candidate
Description

Pharmacological therapeutic candidate targeting Pfeiffer syndrome, one of the most common FGFR2-related Syndromic Craniosynostosis conditions; designed to address the root cause of FGFR2 mutations and restore normal child development without lifelong surgeries.

2Apert Syndrome Therapeutic
CategoryTherapeutic candidate
Description

Pharmacological therapeutic candidate targeting Apert syndrome, an FGFR2-related Syndromic Craniosynostosis condition; part of Krouzon's drug development program focused on disease-modifying treatments for rare pediatric genetic disorders.

3Crouzon Syndrome Therapeutic
CategoryTherapeutic candidate
Description

Pharmacological therapeutic candidate targeting Crouzon syndrome, a FGFR2-related Syndromic Craniosynostosis condition; supported by the world's first disease model for Crouzon syndrome created by Krouzon's founder, enabling discovery of treatment methods.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1ABCT (Accelerator for Biosciences in Connecticut)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Selected as one of 12 High-Potential Life Science Startups for Connecticut's Accelerator Program. The 6.5-month program features business education to develop fundable business plans, professional network access, entrepreneur coaching, active business professional access, and investor pitch preparation.

krouzon.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Krouzon Pharmaceuticals

Rare Pediatric Disease Therapeuticskrouzon.com

Krouzon Pharmaceuticals firmographics

Firmographics
Name
Krouzon Pharmaceuticals
Legal name
Krouzon Pharmaceuticals, Inc.
Website
https://krouzon.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Krouzon Pharmaceuticals industry classification

Industry
Product category
Rare Pediatric Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Craniosynostosis treatment
  • FGFR2 inhibitors
  • Pediatric genetic diseases
  • Pharmaceutical drug development

Where Krouzon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Krouzon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: Pre-revenue biotech company developing pharmacological treatments for rare pediatric diseases. Revenue will be generated through drug commercialization upon regulatory approval, likely via prescription model for orphan/rare disease therapeutics.

Go-to-market motion1 record

Marketing channels3 records

Krouzon Pharmaceuticals product offering

Product offering

Core offering

Krouzon Pharmaceuticals is developing pharmacological therapeutics for children born with FGFR2-related Syndromic Craniosynostosis syndromes — Pfeiffer, Apert, and Crouzon syndromes. The drug development program focuses on creating disease-modifying treatments that target the root cause of FGFR2 mutations, aiming to restore normal child development and eliminate the need for lifelong invasive surgeries that constitute current standard of care.

Product overview

Krouzon Pharmaceuticals is developing a pipeline of pharmacological therapeutics for pediatric rare diseases, specifically targeting FGFR2-related Syndromic Craniosynostosis conditions including Pfeiffer syndrome, Apert syndrome, and Crouzon syndrome. The company's drug development program focuses on creating disease-modifying treatments to restore normal child development without the need for lifelong surgeries. These three therapeutic candidates represent Krouzon's core product portfolio in pediatric rare disease therapeutics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pfeiffer Syndrome Therapeutic Pharmacological therapeutic candidate targeting Pfeiffer syndrome, one of the most common FGFR2-related Syndromic Craniosynostosis conditions; designed to address the root cause of FGFR2 mutations and restore normal child development without lifelong surgeries.
  • Apert Syndrome Therapeutic Pharmacological therapeutic candidate targeting Apert syndrome, an FGFR2-related Syndromic Craniosynostosis condition; part of Krouzon's drug development program focused on disease-modifying treatments for rare pediatric genetic disorders.
  • Crouzon Syndrome Therapeutic Pharmacological therapeutic candidate targeting Crouzon syndrome, a FGFR2-related Syndromic Craniosynostosis condition; supported by the world's first disease model for Crouzon syndrome created by Krouzon's founder, enabling discovery of treatment methods.

Companies that use Krouzon Pharmaceuticals

Customer profile

Segments1 record

Ideal customer profiles1 record

Krouzon Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Krouzon Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ABCT (Accelerator for Biosciences in Connecticut)coreStrategic or Co-development Partner · 1 January 2019Selected as one of 12 High-Potential Life Science Startups for Connecticut's Accelerator Program. The 6.5-month program features business education to develop fundable business plans, professional network access, entrepreneur coaching, active business professional access, and investor pitch preparation.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Krouzon Pharmaceuticals competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Krouzon Pharmaceuticals social profiles

Digital presence

Krouzon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Krouzon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles1 record

Krouzon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Krouzon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Krouzon Pharmaceuticals

What does Krouzon Pharmaceuticals do?

Krouzon Pharmaceuticals is developing pharmacological therapeutics for children born with FGFR2-related Syndromic Craniosynostosis syndromes — Pfeiffer, Apert, and Crouzon syndromes. The drug development program focuses on creating disease-modifying treatments that target the root cause of FGFR2 mutations, aiming to restore normal child development and eliminate the need for lifelong invasive surgeries that constitute current standard of care.

Is Krouzon Pharmaceuticals a public or private company?

Krouzon Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Krouzon Pharmaceuticals founded?

Krouzon Pharmaceuticals was founded in 2016. It employs 1 to 10 people.

Where is Krouzon Pharmaceuticals based?

Krouzon Pharmaceuticals is headquartered in New Haven, United States, in the North America region.

How does Krouzon Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Does Krouzon Pharmaceuticals have an API?

No public API is recorded for Krouzon Pharmaceuticals.

What industry is Krouzon Pharmaceuticals in?

Krouzon Pharmaceuticals's product category is Rare Pediatric Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales